Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
132 hedge funds and large institutions have $215M invested in Esperion Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 20 closing their positions.
328% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $2.4M
184% more capital invested
Capital invested by funds: $75.9M → $215M (+$139M)
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
8% more funds holding
Funds holding: 122 → 132 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 36
8.98% less ownership
Funds ownership: 72.23% → 63.26% (-9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.15M |
| 2 |
Renaissance Technologies
New York
|
+$1.57M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.57M |
| 4 |
WCM
Whitefort Capital Management
New York
|
+$1.15M |
| 5 |
Two Sigma Investments
New York
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.01M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.42M |
| 3 |
Millennium Management
New York
|
-$3.04M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.82M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.56M |
ESPR Hedge Fund Activity: Q4 2023 in Review
132 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2023, worth a combined $215M — up 184% from $75.9M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ESPR positions and 20 closed out — a net gain of 11 holders — while 35 added to existing stakes and 36 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.15M. The largest seller was Point72 Asset Management, cutting an estimated $4.01M.
- 132 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2023, up from 122 in Q3 2023.
- Funds reported $215M of Esperion Therapeutics stock for Q4 2023, up 184% quarter-over-quarter.
- 31 funds opened new Esperion Therapeutics positions in Q4 2023 and 20 closed out, a net change of +11 holders.
- The largest Esperion Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $4.15M added.
- The largest Esperion Therapeutics seller in Q4 2023 was Point72 Asset Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q4 2023.